Apple delayed its AI health coach, Project Mulberry, at WWDC 2026 but is shipping AI sleep-sound detection and an Apple Watch Series 12 with 5-second heart-rate sampling.
Google is retiring the Fitbit brand for a $9.99/month Gemini-powered Health Coach launching May 19, 2026, alongside a new $99.99 Fitbit Air tracker.
A Zhengzhou Normal University study found that a ChatGPT-based depression screening tool, BDI-FS-GPT, achieved 89.3% sensitivity, outperforming the widely used PHQ-9 questionnaire, though researchers caution larger trials are still needed.
Dartmouth's Therabot, developed by psychiatry researchers Michael Heinz and Nicholas Jacobson, is being held up as an example of an AI mental health chatbot built and validated through clinical research rather than consumer trial and error.
New multicenter data presented at the Society of Critical Care Medicine's 2026 Critical Care Congress show Cytovale's AI-interpreted IntelliSep sepsis test cut mortality 19% across four expansion hospitals and more than 34,000 ED patients — though the results come from vendor-linked, pre-post analysis rather than an independent randomized trial.
Ono Pharmaceutical has partnered with Aitia to use causal AI 'digital twins' to identify new drug targets for hard-to-treat neurological diseases, joining a wave of 2026 pharma-AI deals betting that modeling cause and effect — not just correlation — can finally move the needle on brain disease drug discovery.
Oura has built a proprietary AI model dedicated to women's health that blends clinician-vetted research with a user's own biometric data, aiming to give more trustworthy answers on cycles, pregnancy and menopause than generic search results.
Mount Sinai has embedded OpenEvidence's AI clinical decision support tool directly into its Epic health record, letting physicians, nurses and pharmacists across seven hospitals query peer-reviewed medical evidence in natural language without leaving the patient chart.
A new market report details how Cleveland Clinic and Mayo Clinic have expanded AI enterprise-wide across outpatient surgery — from predictive risk models to post-discharge monitoring — as investors pour hundreds of millions into surgical AI startups.
A new market analysis shows AI-assisted pathology moving from pilot projects to routine clinical use, spotlighting PathAI's $165 million funding round and its expanded Labcorp partnership — even as independent clinical-outcome trials won't report results until 2029.